Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (181-190 of 324) with videos related to

Pageof 33
Sort By:
AIDS (London, England)|March 3, 2015
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levelsWilliam J Hey-Cunningham, John M Murray, Ven Natarajan, et al.
AIDS (London, England)|July 2, 2014
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsDavid A Cooper, Jayvant Heera, Prudence Ive, et al.
Plos One|February 21, 2012
Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infectionSarah C Sasson, John J Zaunders, Nabila Seddiki, et al.
Antiviral Therapy|February 5, 2008
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimenReshma S Autar, Mark A Boyd, Ferdinand W M N Wit, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2003
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjectsMark A Boyd, Rob E Aarnoutse, Kiat Ruxrungtham, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2013
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trialPietro Vernazza, Cunshan Wang, Anton Pozniak, et al.
Antiviral Therapy|October 13, 2005
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patientsJintanat Ananworanich, Andrew Hill, Umaporn Siangphoe, et al.
Plos Pathogens|August 26, 2016
Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 DaysMykola Pinkevych, Stephen J Kent, Martin Tolstrup, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 28, 2011
Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapyScott L Butler, Hernan Valdez, Michael Westby, et al.
AIDS Research and Human Retroviruses|August 27, 2013
The majority of HIV type 1 DNA in circulating CD4+ T lymphocytes is present in non-gut-homing resting memory CD4+ T cellsKristin McBride, Yin Xu, Michelle Bailey, et al.
Pageof 33

Showing results (181-190 of 324) with videos related to

Sort By:
Pageof 33
AIDS (London, England)|March 3, 2015
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levelsWilliam J Hey-Cunningham, John M Murray, Ven Natarajan, et al.
AIDS (London, England)|July 2, 2014
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsDavid A Cooper, Jayvant Heera, Prudence Ive, et al.
Plos One|February 21, 2012
Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infectionSarah C Sasson, John J Zaunders, Nabila Seddiki, et al.
Antiviral Therapy|February 5, 2008
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimenReshma S Autar, Mark A Boyd, Ferdinand W M N Wit, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2003
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjectsMark A Boyd, Rob E Aarnoutse, Kiat Ruxrungtham, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 19, 2013
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trialPietro Vernazza, Cunshan Wang, Anton Pozniak, et al.
Antiviral Therapy|October 13, 2005
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patientsJintanat Ananworanich, Andrew Hill, Umaporn Siangphoe, et al.
Plos Pathogens|August 26, 2016
Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 DaysMykola Pinkevych, Stephen J Kent, Martin Tolstrup, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 28, 2011
Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapyScott L Butler, Hernan Valdez, Michael Westby, et al.
AIDS Research and Human Retroviruses|August 27, 2013
The majority of HIV type 1 DNA in circulating CD4+ T lymphocytes is present in non-gut-homing resting memory CD4+ T cellsKristin McBride, Yin Xu, Michelle Bailey, et al.
Pageof 33